TP53 and neoplasm: Furthermore, our study did not address other molecular alterations such as TP53 mutations or Loss of Y chromosome, which—together with HPV status and immunological markers like IL-12—may interactively shape the tumour microenvironment and ultimately influence immune responsiveness and clinical outcomes.